Perioperative Camrelizumab and Apatinib for High‐Risk Resectable Hepatocellular Carcinoma: A Phase II Study
Perioperative camrelizumab combined with apatinib demonstrated promising efficacy and manageable safety in high‐risk resectable HCC.
2 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Perioperative camrelizumab combined with apatinib demonstrated promising efficacy and manageable safety in high‐risk resectable HCC.
Xenophagy is a selective autophagy process crucial for eliminating intracellular pathogens, yet its regulatory mechanisms remain poorly defined. In this study, acetylome profiling identifies dynamic acetylation of the xenophagy receptor NDP52 at K202, and its deacetylation enhances during Salmonella Typhimurium infecti...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.